Hoya’s Reports Strong IOL Sales in Fiscal 2017 Fourth Quarter

May 12, 2017: By Jon Swedien

Hoya logoHoya’s intraocular lens (IOL) sales were strong during its fiscal 2017 fourth quarter—Jan. 1 to March 31, 2017, according to the Japanese company.

The firm announced May 11 that its IOL sales for cataracts continued to perform well in Japan, after being introduced in the previous fiscal year. Outside of Japan, IOL sales grew, outpacing performance for the same period in the prior fiscal year “by a significant margin,” Hoya said.

Hoya’s Life Care business segment, which includes eyeglass lenses, contact lenses, and intraocular lenses (IOLs), plus other products, saw an increase in revenues of 3.5 percent, with sales totaling 83,752 million yen (US $739 million, as of May 12, 2017) in the quarter.

Hoya reported that its overall revenues increased 3.8 percent to 126,304 million yen (US $1.12 billion) in the company’s 2017 fiscal fourth quarter.

Revenues for the fiscal year ended March 31, 2017, totaled 478,927 million yen (US $4.23 billion), down 5.3 percent year over year.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Ophthalmic Devices Panel to hold Meeting Oct. 27

Novartis’ RTH258 Successful in Two Phase III Studies for nAMD

Ocugen Closes $7.5 Million Series B Round

Genentech Uses Vital Art and Science Vision-Testing App in Phase II Study of Sustained Delivery of Lucentis

US Supreme Court Ruling Shortens Time to Market for Biosimilars

Ellex Acquires Royalty Commitment for iTrack Device for $2.15 Million

Johnson & Johnson Vision Names Jonathan Talamo, MD, Chief Medical Officer

Teva Launches Generic Versions of Pataday in US

David Karcher Stepping Down as Executive Director, CEO of ASCRS

EyeGate Raises $10 Million in Public Offering

Aerie Raises $125 Million through Upsized Public Offering, ATM Program

pSivida’s Durasert for Posterior Segment Uveitis Successful in Second Phase III Study

Mynosys Zepto Receives US FDA 510(k) Clearance

Ozurdex, Humira Gain NICE Backing for Non-infectious Posterior Uveitis

Roger Steinert, Pioneer in Ophthalmology, Dies at 66

Carl Zeiss Meditec to Build New Innovation Center in Northern California

Gottlieb Says FDA to Publish List of Drugs Without Generic Competition

REGENXBIO Announces Phase I Clinical Trial for RGX-314 Gene Therapy for Wet AMD

Belkin Laser Closes Nearly $5 Million Financing Round

Valeant in Talks to Sell Surgical Business to Carl Zeiss Meditec

Coming soon

2017 Cataract Surgical Equipment: A Global Market Analysis for 2016 to 2022